Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ustekinumab induction and maintenance in pediatric ulcerative colitis
2023-504977-19-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Subcutaneous Stelara maintenance with Subcutaneous placebo maintenance (2 arms). Primary endpoint: Clinical remission at Week I-8. Started Aug 2023; status: completed.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-504977-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504977-19-00.